SEC Form 4													
FOF	RM 4	UNI	TED STAT	SION									
Check this box if Section 16. Form obligations may Instruction 1(b).		S		T OF CHAN	6(a) of	the Se	ecurities Excha	nge Act	of 1934	Estin	Number: nated average burd s per response:	3235-0287 len 0.5	
contract, instruct the purchase or securities of the to satisfy the affi	made pursuant to a ion or written plan for sale of equity issuer that is intended						,						
1. Name and Address of Reporting Person [*] Jain Vivek				2. Issuer Name and ⊺ CU MEDICA				(Chec	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify below) Chairman and CEO				
(Last) (First) (Middle) 951 CALLE AMANECER				3. Date of Earliest Tra 1/01/2024	ansactic	on (Mo	nth/Day/Year)						
(Street) SAN CLEMENTE (City)	CA (State)	92673 (Zip)		i. If Amendment, Dat	endment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Chu Line) V Form filed by One Reporting Form filed by More than One Person						e Reporting Pers	on	
		Table I -	Non-Derivat	ive Securities /	Acqui	red,	Disposed o	of, or l	Beneficially	Owned			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year	Execution Date,		action (Instr.	4. Securities Acquired (A) or D Of (D) (Instr. 3, 4 and 5) Amount (A) or Price) [`] `````	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature o Indirect Beneficial Ownership (Instr. 4)	
Common Stock			11/01/2024		М		12,000(1)	A	\$88.76	116,593	D		

(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Non- Qualified Stock Option (right to buy)	\$ 88.76	11/01/2024		М			12,000 ⁽¹⁾	02/11/2018	02/11/2025	Common Stock	12,000	\$0.0	13,373	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

S

S

s

s

4.228(2)

4,147(2)

2,386(2)

1,239(2)

D

D

D

D

\$170,7504⁽³⁾

\$171.9086(4)

\$172.7628(5)

\$173.597(6)

112.365

108,218

105,832

104,593

88,698

D

D

D

D

Ι

by Trust

Explanation of Responses:

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

1. The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

11/01/2024

11/01/2024

11/01/2024

11/01/2024

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$170.28 to \$171.23, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$171.25 to \$172.23, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$172.275 to \$173.175, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$173.44 to \$173.91, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

By: Paula Darbyshire, Attorney-11/04/2024 in-fact For: Vivek Jain

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.